Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Andrew Ahmann

Article Type

Case Report

Published

Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of antidiabetes agents with an insulin-independent mechanism of action, making them suitable for use in combination with any other class of antidiabetes agents, including insulin. In this review the evaluates a 78-week, randomized, double-blind, placebo controlled trial investigating the impact of empagliflozin, an SGLT2 inhibitor, as add-on to basal insulin in patients with inadequate glycemic control on basal insulin, with or without metformin and/or a sulfonylurea.

Read more

A review of current treatment strategies for gestational diabetes mellitus

Kristi W Kelley, Dana G Carroll, Allison Meyer

Article Type

Review

Published

Once changes in lifestyle have failed, treatment for gestational diabetes mellitus remains a matter of debate. In this article the authors review the evidence for glyburide and metformin, and discuss the role of insulin. Also, recommendations for postpartum screening and how to manage patients who are breastfeeding are described.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.